Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM

Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM

The administration of Covid-19 convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19 did not prevent disease progression. (SIREN-C3PO ClinicalTrials.gov number, NCT04355767. opens in new tab.)

Comments

Popular posts from this blog

The conflict in Gaza: a view from Israel - The Lancet

George F. Will - Skip the lecture on Israel's 'risks for peace'